NCT01139515

Eletriptan Pharmacokinetics In Korean Males

An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Eletriptan commercial tablet	20 mg tablet, single dose
DRUG	Eletriptan commercial tablet	40 mg tablet, single dose of 1 X 40 mg
DRUG	Eletriptan commercial tablet	40 mg tablet, single dose of 2 X 40 mg
DRUG	Eletriptan commercial tablet	40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first

Timeline

• Start date: 2010-07-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2010-06-08
• Last updated: 2021-01-28
• Results posted: 2011-07-12

Locations

1 site across 1 country: South Korea